FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1607354400> ?p ?o ?g. }

• W1607354400 endingPage "2876" @default.
• W1607354400 startingPage "2869" @default.
• W1607354400 abstract "The LUX-Lung 3 study investigated the efficacy of chemotherapy compared with afatinib, a selective, orally bioavailable ErbB family blocker that irreversibly blocks signaling from epidermal growth factor receptor (EGFR/ErbB1), human epidermal growth factor receptor 2 (HER2/ErbB2), and ErbB4 and has wide-spectrum preclinical activity against EGFR mutations. A phase II study of afatinib in EGFR mutation-positive lung adenocarcinoma demonstrated high response rates and progression-free survival (PFS).In this phase III study, eligible patients with stage IIIB/IV lung adenocarcinoma were screened for EGFR mutations. Mutation-positive patients were stratified by mutation type (exon 19 deletion, L858R, or other) and race (Asian or non-Asian) before two-to-one random assignment to 40 mg afatinib per day or up to six cycles of cisplatin plus pemetrexed chemotherapy at standard doses every 21 days. The primary end point was PFS by independent review. Secondary end points included tumor response, overall survival, adverse events, and patient-reported outcomes (PROs).A total of 1,269 patients were screened, and 345 were randomly assigned to treatment. Median PFS was 11.1 months for afatinib and 6.9 months for chemotherapy (hazard ratio [HR], 0.58; 95% CI, 0.43 to 0.78; P = .001). Median PFS among those with exon 19 deletions and L858R EGFR mutations (n = 308) was 13.6 months for afatinib and 6.9 months for chemotherapy (HR, 0.47; 95% CI, 0.34 to 0.65; P = .001). The most common treatment-related adverse events were diarrhea, rash/acne, and stomatitis for afatinib and nausea, fatigue, and decreased appetite for chemotherapy. PROs favored afatinib, with better control of cough, dyspnea, and pain.Afatinib is associated with prolongation of PFS when compared with standard doublet chemotherapy in patients with advanced lung adenocarcinoma and EGFR mutations." @default.
• W1607354400 created "2016-06-24" @default.
• W1607354400 creator A5005314279 @default.
• W1607354400 creator A5005875420 @default.
• W1607354400 creator A5005962138 @default.
• W1607354400 creator A5028553204 @default.
• W1607354400 creator A5032337115 @default.
• W1607354400 creator A5033519199 @default.
• W1607354400 creator A5036507802 @default.
• W1607354400 creator A5038687249 @default.
• W1607354400 creator A5043397424 @default.
• W1607354400 creator A5047152744 @default.
• W1607354400 creator A5048057712 @default.
• W1607354400 creator A5052978985 @default.
• W1607354400 creator A5053546904 @default.
• W1607354400 creator A5055074037 @default.
• W1607354400 creator A5072123060 @default.
• W1607354400 creator A5077287358 @default.
• W1607354400 creator A5081587983 @default.
• W1607354400 creator A5085339887 @default.
• W1607354400 creator A5091073688 @default.
• W1607354400 creator A5091450277 @default.
• W1607354400 date "2023-06-01" @default.
• W1607354400 modified "2023-09-25" @default.
• W1607354400 title "Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations" @default.
• W1607354400 doi "https://doi.org/10.1200/jco.22.02547" @default.
• W1607354400 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37235976" @default.
• W1607354400 hasPublicationYear "2023" @default.
• W1607354400 type Work @default.
• W1607354400 sameAs 1607354400 @default.
• W1607354400 citedByCount "2" @default.
• W1607354400 countsByYear W16073544002023 @default.
• W1607354400 crossrefType "journal-article" @default.
• W1607354400 hasAuthorship W1607354400A5005314279 @default.
• W1607354400 hasAuthorship W1607354400A5005875420 @default.
• W1607354400 hasAuthorship W1607354400A5005962138 @default.
• W1607354400 hasAuthorship W1607354400A5028553204 @default.
• W1607354400 hasAuthorship W1607354400A5032337115 @default.
• W1607354400 hasAuthorship W1607354400A5033519199 @default.
• W1607354400 hasAuthorship W1607354400A5036507802 @default.
• W1607354400 hasAuthorship W1607354400A5038687249 @default.
• W1607354400 hasAuthorship W1607354400A5043397424 @default.
• W1607354400 hasAuthorship W1607354400A5047152744 @default.
• W1607354400 hasAuthorship W1607354400A5048057712 @default.
• W1607354400 hasAuthorship W1607354400A5052978985 @default.
• W1607354400 hasAuthorship W1607354400A5053546904 @default.
• W1607354400 hasAuthorship W1607354400A5055074037 @default.
• W1607354400 hasAuthorship W1607354400A5072123060 @default.
• W1607354400 hasAuthorship W1607354400A5077287358 @default.
• W1607354400 hasAuthorship W1607354400A5081587983 @default.
• W1607354400 hasAuthorship W1607354400A5085339887 @default.
• W1607354400 hasAuthorship W1607354400A5091073688 @default.
• W1607354400 hasAuthorship W1607354400A5091450277 @default.
• W1607354400 hasConcept C121608353 @default.
• W1607354400 hasConcept C126322002 @default.
• W1607354400 hasConcept C143998085 @default.
• W1607354400 hasConcept C203092338 @default.
• W1607354400 hasConcept C2776256026 @default.
• W1607354400 hasConcept C2776694085 @default.
• W1607354400 hasConcept C2777240266 @default.
• W1607354400 hasConcept C2778239845 @default.
• W1607354400 hasConcept C2779438470 @default.
• W1607354400 hasConcept C2780580887 @default.
• W1607354400 hasConcept C2780586478 @default.
• W1607354400 hasConcept C2781182431 @default.
• W1607354400 hasConcept C31760486 @default.
• W1607354400 hasConcept C535046627 @default.
• W1607354400 hasConcept C71924100 @default.
• W1607354400 hasConcept C90924648 @default.
• W1607354400 hasConceptScore W1607354400C121608353 @default.
• W1607354400 hasConceptScore W1607354400C126322002 @default.
• W1607354400 hasConceptScore W1607354400C143998085 @default.
• W1607354400 hasConceptScore W1607354400C203092338 @default.
• W1607354400 hasConceptScore W1607354400C2776256026 @default.
• W1607354400 hasConceptScore W1607354400C2776694085 @default.
• W1607354400 hasConceptScore W1607354400C2777240266 @default.
• W1607354400 hasConceptScore W1607354400C2778239845 @default.
• W1607354400 hasConceptScore W1607354400C2779438470 @default.
• W1607354400 hasConceptScore W1607354400C2780580887 @default.
• W1607354400 hasConceptScore W1607354400C2780586478 @default.
• W1607354400 hasConceptScore W1607354400C2781182431 @default.
• W1607354400 hasConceptScore W1607354400C31760486 @default.
• W1607354400 hasConceptScore W1607354400C535046627 @default.
• W1607354400 hasConceptScore W1607354400C71924100 @default.
• W1607354400 hasConceptScore W1607354400C90924648 @default.
• W1607354400 hasIssue "16" @default.
• W1607354400 hasLocation W16073544001 @default.
• W1607354400 hasLocation W16073544002 @default.
• W1607354400 hasOpenAccess W1607354400 @default.
• W1607354400 hasPrimaryLocation W16073544001 @default.
• W1607354400 hasRelatedWork W2239879423 @default.
• W1607354400 hasRelatedWork W2358450743 @default.
• W1607354400 hasRelatedWork W2408182535 @default.
• W1607354400 hasRelatedWork W2549473871 @default.
• W1607354400 hasRelatedWork W2906574801 @default.
• W1607354400 hasRelatedWork W2979271184 @default.
• W1607354400 hasRelatedWork W2979585789 @default.
• W1607354400 hasRelatedWork W3042289395 @default.

• next